Mumbai February 10, 2013:- After the US Food and Drug Administration (USFDA) raised concerns over Ranbaxy’s largest drug ingredient plant at Toansa, many questions regarding the GMP compliance have come up. The company is making every attempt to investigate these issues and aims at resolving them.
During the company’s internal investigations, certain preliminary findings have called attention. These findings point towards a possibility that some of the good manufacturing practice (GMP) violations that the FDA inspectors observed at the Toansa plant could have been framed by some dissatisfied employees. This needs further investigations before concluding anything. – GMP
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…